GUT DYSBIOSIS IN THE ADENOMA-CARCINOMA SEQUENCE: A COMPREHENSIVE REVIEW OF CLINICAL AND PRECLINICAL EVIDENCE
Authors:
- Paulina BiedrońPBPaulina Biedroń
- Anna SkrzypekASAnna Skrzypek
- Maciej HutkowskiMHMaciej Hutkowski
- Mikołaj ZbrożekMZMikołaj Zbrożek
- Zuzanna ChwostekZCZuzanna Chwostek
- Bartłomiej KosiarskiBKBartłomiej Kosiarski
- Patrycja MarkowiczPMPatrycja Markowicz
- Hanna MaruchniakHMHanna Maruchniak
- Wiktoria MarzecWMWiktoria Marzec
- Krzysztof BiłykKBKrzysztof Biłyk
Open Access
- 6 January 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Abstract
Background: Colorectal cancer (CRC) is a major oncological challenge increasingly linked to gut microbiota dysbiosis. Microbial alterations are believed to drive the progression from benign precursor lesions to invasive cancer along the adenoma-carcinoma sequence. Aim: The aim of this review is to summarize current knowledge about the role of microbial alterations in the adenoma-carcinoma sequence, focusing on specific pro-tumorigenic pathogens - specifically Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis (ETBF), and pks+ Escherichia coli and their pathogenic mechanisms. Material and methods: A literature review was conducted using PubMed and Google Scholar, focusing on articles published in English within the last eight years with a particular focus on recent evidence from 2019 to 2025. The search prioritized metagenomic analyses and preclinical studies regarding CRC, dysbiosis, and specific bacterial drivers using terms such as ‘colorectal cancer’, ‘adenoma-carcinoma sequence’, and ‘gut microbiota’. Results: Dysbiosis appears early in carcinogenesis, characterized by the depletion of beneficial butyrate-producers and expansion of pathobionts. Key pathogens drive tumorigenesis through distinct mechanisms, including toxin production (e.g., BFT, colibactin), DNA damage, and immune modulation. Functional evidence from murine models confirms a causal link, demonstrating that dysbiotic microbiota actively accelerates tumor growth and inflammation. Conclusions: Intestinal dysbiosis is a fundamental, early driver of CRC pathogenesis, not merely a passive consequence. Identifying oncogenic bacteria offers new perspectives for early non-invasive diagnosis and therapeutic strategies to inhibit disease progression.Keywords
This publication has 43 references indexed in Scilit:
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategiesJournal of Advanced Research, 2025
- Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatmentDiscover Oncology, 2025
- The emerging role of bacterial extracellular vesicles in human cancersJournal of Extracellular Vesicles, 2024
- Gut microbiota alterations in colorectal adenoma-carcinoma sequence based on 16S rRNA gene sequencing: A systematic review and meta-analysisMicrobial Pathogenesis, 2024
- Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapyCancer Communications, 2022
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapyEBioMedicine, 2019
- Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin/+ miceEBioMedicine, 2019
- Environmental Factors, Gut Microbiota, and Colorectal Cancer PreventionClinical Gastroenterology and Hepatology, 2019
- Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicineThe Journal of Pathology, 2018